DEF 14A: Cartesian Therapeutics Seeks Stockholder Approval for Series B Preferred Stock Conversion

Cartesian Therapeutics is holding a special meeting on September 20, 2024, to seek stockholder approval for the conversion of its Series B Preferred Stock into common stock.

Summary

• Cartesian Therapeutics is convening a special meeting of stockholders on September 20, 2024, to vote on two proposals.
• The first proposal seeks approval for the issuance of common stock upon conversion of the company's Series B Non-Voting Convertible Preferred Stock, as required by Nasdaq Listing Rule 5635(d).
• The second proposal concerns the adjournment or postponement of the special meeting if necessary to continue soliciting votes for the first proposal.
• Stockholders of record as of July 29, 2024, are eligible to vote.
• The Board of Directors recommends voting FOR both proposals.
• As of the record date, there were 21,382,485 shares of common stock outstanding.
• Additionally, there were 2,937,903 shares of Series B Preferred Stock and 166,341.592 shares of Series A Preferred Stock outstanding, neither of which are entitled to vote on these matters.
• 3,563,247 shares of common stock issued in a private placement in July 2024 are not entitled to vote on Proposal No. 1 per Nasdaq rules.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating a neutral to slightly positive sentiment. The company is seeking approval for a corporate action that could simplify its capital structure. However, there are inherent risks and uncertainties associated with the outcome of the vote.

Positives

• The conversion of Series B Preferred Stock into common stock could simplify the company's capital structure.
• The Board of Directors unanimously recommends voting in favor of the proposals, indicating confidence in the company's direction.

Negatives

• If stockholders do not approve the conversion, the Series B Preferred Stock held by certain directors and their affiliates may have little value.
• The need for a special meeting and proxy solicitation indicates potential uncertainty or difficulty in securing the necessary votes.

Risks

• Failure to obtain stockholder approval for the conversion could negatively impact the company's ability to raise capital or pursue strategic initiatives.
• The concentration of ownership among a few principal stockholders could give them significant influence over the company's affairs.
• The forward-looking statements are subject to risks and uncertainties detailed in the company's SEC filings.

Future Outlook

The company's future outlook depends on obtaining stockholder approval for the conversion of the Series B Preferred Stock and successfully executing its business strategy. The company's expectations regarding the conversion of the Series B Preferred Stock and Series A Preferred Stock are forward-looking statements and subject to risks and uncertainties.

Management Comments

• The Board of Directors has determined that the proposals are advisable, fair, and in the best interests of Cartesian's stockholders.
• The Board of Directors recommends that stockholders vote FOR each of the proposals.

Industry Context

This announcement is typical for companies seeking to comply with Nasdaq listing rules regarding the issuance of shares and maintain flexibility in their capital structure. Many biotech companies utilize preferred stock to raise capital.

Comparison to Industry Standards

• The use of convertible preferred stock is a common financing mechanism in the biotechnology industry, allowing companies to raise capital while deferring dilution until certain conditions are met.
• Many companies such as BioNTech, Moderna, and CRISPR Therapeutics have used similar financing strategies.
• The specific terms of the Series B Preferred Stock, such as the conversion ratio and beneficial ownership limitations, are tailored to the company's specific circumstances and investor preferences.

Related Party Transactions

• Dr. Timothy A. Springer, a member of the Board of Directors, purchased 1,636,832 shares of Series B Preferred Stock in the Private Placement.
• TAS Partners LLC, an affiliate of Dr. Springer, purchased 721,361 shares of Series B Preferred Stock in the Private Placement.
• Dr. Chafen Lu, Dr. Springer's spouse, purchased 1,307 shares of Series B Preferred Stock in the Private Placement.

Stakeholder Impact

• Approval of the conversion proposal could impact shareholders by potentially diluting their ownership stake.
• Failure to approve the conversion could negatively impact the value of the Series B Preferred Stock held by certain investors, including directors and their affiliates.

Next Steps

• Stockholders need to vote on the proposals before the Special Meeting on September 20, 2024.
• The company will announce preliminary voting results at the Special Meeting and report the final results in a Current Report on Form 8-K.

Key Dates

Keywords

Series B Preferred Stock, Common Stock, Conversion, Proxy Statement, Special Meeting, Stockholder Approval, Cartesian Therapeutics, Nasdaq